Germany's STADA buying Biopharma's pharmaceutical business of prescription, OTC preparations
Germany's STADA pharmaceutical company is acquiring pharmaceutical business of prescription and OTC preparations of Biopharma blood product manufacturer.
According to a STADA press release on Monday, Biopharma's pharmaceutical business will become an integral part of STADA in Ukraine and has strong growth potential in the production of high-quality prescription and OTC drugs.
The agreement provides for the acquisition of production facilities in the city of Bila Tserkva (Kyiv region).
Biopharma shareholders will preserve the company's plasma processing business and focus on its development both in Ukraine and abroad. To acquire it STADA must obtain permission to merge in Ukraine.
The transaction is expected to close in December 2019.
Advertising
Advertising
MORE ABOUT
Pharmaceutical firm Darnitsa could attract loans of up to UAH 5 bln within one year
21:01, 30.04.2024
Activists propose ban intl pharmaceutical companies that continue work in Russia from taking part in state tenders
18:52, 18.08.2022
Pharmaceutical distributor Venta transfers corporate rights belonging to Russian company to ARMA management
12:29, 10.08.2022
Some foreign pharma companies decide not to cooperate with Ukraine, but majority submits proposals for procurement - MPU
16:36, 10.06.2022
Pharmaceutical company Darnytsia supplies free medicines worth UAH 26.6 mln since beginning of war, needs drivers
11:07, 17.03.2022
LATEST
Southern cluster of TAS Agro will sow sunflower on 2,764 ha in 2025 season
20:37, 03.04.2025
EBRD, IFC and Black Sea Trade and Development Bank provide Galnaftogaz with EUR157 mln loan for 147 MW wind farm in Volyn
17:29, 03.04.2025
Ukraine will be able to ensure predictability of trade flows to EU – Kachka
15:39, 03.04.2025
U.S. 10% tariff to hit small manufacturers the hardest, but efforts underway to improve conditions – Ukraine's Deputy PM
12:16, 03.04.2025
Trump announces introduction of reciprocal tariffs on imports, Ukraine receives 10%